From: Conventional therapy for genital herpesvirus and remission of HPV-related lesions: a case series
ID | Age | Genital HHV-2 | PAP TEST HPV-DNA | Condylomatosis | Other STI | Oral antiviral dosage | ACV/VCV topical dosage | Times of remission (d, m, y) |
---|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | G | H | I |
6 | 27 | Cervical lesions | ASCUS HPV16-HPV66 | Vulvar micro-condylomatosis | Severe candidiasis | VCV 3000 mg/d/90d | No | 2 m |
12 | 39 | Vulvar lesions | NILM | Vulvar micro-condylomatosis | (Past laser treatment of CIN2) | ACV 1600 mg/d/15d | No, due to vulvodynia | 20d |
17 | 27 | Vulvar lesions | L-SIL HPV16-HPV42 | Vulvar condylomatosis | Candidiasis | VCV 2000 mg/d/30d | 5% (2x/d/20d) | 2 m |
25 | 40 | Vulvar and cervical lesions | NILM | Vulvar micro-condylomatosis | Vulvo-perineal candidiasis | ACV 1600 mg/d/15d | 5% (3x/d/10d) 2 times with 7d interval | 15d |
29 | 42 | Cervical lesions | L-SIL HPV negative | Vulvar micro-condylomatosis | Candidiasis | VCV 1000 mg/d/42d | No | 5 m |
32 | 40 | Vulvar HHV-2 recurrent | H-SIL CIN2 HPV16 | Perineal and anal condylomatosis | Candidiasis | VCV 2000 mg/d/90d | 5% (1x/d/45d) | 6 m |
37 | 48 | Vulvar lesions | LSIL HPV16 | nd | nd | 5% ACV (intravaginal appl 4x/d/15d) 4 times with 7d interval | 7 m |